ARTIOS PHARMA ANNOUNCES FIRST CLINICAL STUDY REGARDING ADVANCED NEXT-GEN DDR

HIGHLIGHTS

  • Artios Pharma is now turning into a clinical-stage precision medicine company.
  • Artios Pharma is advancing the next generation DDR treatment.

Known to be a leading DNA Damage Response (DDR) company, Artios Pharma Limited has been developing a broad pipeline of precision medicines for a long time that can be useful for the treatment of cancer. Now it has announced a new venture regarding the beginning of a clinical trial of its small-molecule ataxia telangiectasia and Rad3-related kinase (ATR) inhibitor called ART0380. It is going to be helpful for patients with advanced or metastatic solid tumors.

ShangPharma Innovation and the University of Texas MD Anderson Cancer Center licensed ART0380 in 2019. This molecule was jointly developed as part of a collaboration between MD Anderson’s Therapeutics Discovery Division and ShangPharma.

The clinical trial of the ATR inhibitor is a multi-center, open-label, Phase I/IIA study that has been designed to evaluate the pharmacokinetics, safety, tolerability, and preliminary efficacy of ART0380 as a monotherapy. It also intends to evaluate ART0380 in combination with gemcitabine in patients who have advanced solid cancers or metastatic solid cancers. The study is going to enroll up to 180 patients and will be conducted at multiple oncology centers across the USA, UK, and many other countries of Europe.

Niall Martin, Chief Executive Officer (CEO) of Artios Pharma said that his vision was the success of Poly-ADP Ribose Polymerase (PARP) inhibition to enable more patients to benefit from DDR targeting medicines. ADP stands for Adenosine diphosphate.